Knowing prior methicillin-resistant Staphylococcus aureus (MRSA) infection or colonization status increases the...

Area of Science:

• Infectious Diseases
• Clinical Microbiology
• Hospital Epidemiology

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia poses a significant clinical challenge.
• Understanding the impact of known MRSA colonization status on patient outcomes is crucial for effective management.
• Existing data on the differential management and outcomes based on prior MRSA status are limited.

Purpose of the Study:

• To compare the clinical management and outcomes of MRSA bacteremia in patients with known MRSA colonization/infection (C-patients) versus those without (NC-patients).
• To evaluate the association between known MRSA status and mortality in patients with MRSA bacteremia.
• To identify potential factors contributing to outcome differences, such as empirical antibiotic therapy.

Main Methods:

• A 10-year retrospective review of MRSA bacteremia cases in an adult tertiary hospital.
• Clinical data extraction via chart review and mortality data from linked databases.
• Analysis of empirical therapy choices and patient characteristics based on known MRSA colonization status.

Main Results:

• Known MRSA colonization status was available for 35.4% of MRSA bacteremia episodes.
• C-patients received empirical glycopeptides more frequently (49.3% vs. 18.9%, p <0.01).
• All-cause 7-day mortality was lower in C-patients (7.5% vs. 18.9%, p=0.04), and known colonization status was associated with significantly lower 30-day mortality (p <0.01).

Conclusions:

• Mortality from MRSA bacteremia is lower in patients with known MRSA colonization status.
• Earlier initiation of glycopeptide therapy in C-patients may contribute to improved outcomes.
• Suboptimal empirical glycopeptide use in known MRSA-colonized patients represents a missed opportunity for infection control and improved clinical management.